MedTrace Logo

Biomarkers of Trained Immunity Following MMR Vaccination

NCT04646239 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2021-11-26

No results posted yet for this study

Summary

This is a substudy of NCT04333732. The goal of this sub-study is to identify and characterize biomarkers of trained immunity by measuring, in vitro, immune responses to heterologous products, especially viral associated products, in the MMR vaccinated compared placebo groups.

All participants are randomly assigned to MMR or placebo injection at baseline, followed by SARS-CoV-2 specific vaccination. Blood is drawn around 60 to 90 days after the last SARS-CoV-2 specific vaccine injection.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

Heterologous stimuli

In vitro exposure of peripheral blood mononuclear cells to heterologous stimuli

DIAGNOSTIC_TEST

Neutralization assay

In vitro measurement of neutralizing antibody activity to wild-type SARS-CoV-2

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Michael S Avidan, MD · Washington Univeristy School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-17
Primary Completion
2021-06-28
Completion
2021-06-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04646239 on ClinicalTrials.gov